Phase I Trial Design
How Phase I trials establish drug safety in humans through dose-escalation designs and pharmacokinetic profiling.
## Purpose of Phase I Trials
Phase I trials are the first time a drug is tested in humans. Their primary objective is to evaluate safety and tolerability, not therapeutic efficacy. Researchers determine the maximum tolerated dose (MTD), characterize how the body processes the drug (pharmacokinetics), and identify dose-limiting toxicities.
## Study Populations
Most Phase I trials enroll 20-80 healthy adult volunteers because their lack of disease-related physiological changes provides cleaner pharmacokinetic data. Important exceptions include oncology and rare disease trials, where healthy volunteers cannot ethically be exposed to cytotoxic or highly targeted agents. In these cases, patients with the target disease who have exhausted standard treatments serve as Phase I participants.
## Dose-Escalation Designs
### 3+3 Design
The traditional approach enrolls three participants at a starting dose. If no dose-limiting toxicity (DLT) occurs, the next cohort receives a higher dose. If one of three experiences a DLT, three more are enrolled at the same level. If two or more of six experience DLTs, that dose exceeds the MTD.
### Accelerated Titration
A single participant receives each dose level, with escalation proceeding rapidly until a predefined toxicity signal appears, at which point the design reverts to standard 3+3 cohorts. This reduces the number of participants exposed to sub-therapeutic doses.
### Model-Based Designs (CRM)
The Continual Reassessment Method uses Bayesian statistical modeling to estimate the dose-toxicity relationship after each cohort. This approach is more efficient than rule-based designs and can identify the MTD with fewer participants.
## Pharmacokinetic Assessment
Phase I trials generate absorption, distribution, metabolism, and excretion (ADME) profiles. Key parameters measured include Cmax, Tmax, AUC, half-life, clearance, and volume of distribution. Single ascending dose (SAD) studies precede multiple ascending dose (MAD) studies to evaluate accumulation at steady state.
## Food Effect and Drug Interaction Studies
Phase I commonly includes food-effect studies comparing fasted and fed pharmacokinetics, and preliminary drug-drug interaction studies with common co-medications.
## Key Takeaways
- Phase I primarily assesses safety, tolerability, and pharmacokinetics
- The 3+3 design remains standard, but model-based approaches are gaining adoption
- Healthy volunteers are typical participants except in oncology and rare diseases
- PK parameters from Phase I directly inform dose selection for Phase II
- Approximately 70% of drugs pass Phase I successfully